ArticleVirology journal2025
Viral characterization of the reassortants between canine influenza H3N2 and human pandemic (2009) H1N1 and avian H9N2 viruses in canine ex vivo tracheal explants.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Acquisition of amantadine resistance via M gene reassortment in canine H3N2 influenza virus and elucidation of the resistance mechanism.Virology journal · 2026Article
- Mammalian adaptation and zoonotic risk of influenza A viruses in companion animals.Journal of veterinary science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundIn 2007, the canine influenza H3N2 virus (H3N2-CIV) first emerged in the canine population in South Korea. The virus had since spread internationally and continues to circulate in the canines. While there is currently no report of H3N2-CIV spilling over to the human population, the virus had shown a tendency to reassort with other influenza subtypes. Given that the canine respiratory tract is susceptible to a wide range of influenza viruses, it is of interest whether H3N2-CIV are likely to reassort with human and avian IAVs to generate reassortants with increased zoonotic potential.
methodsWe conducted a co-infection study in canine tracheal explants. Ex vivo canine tracheal tissues were co-infected by H3N2-CIV and two respective human and avian influenza viruses, 2009 pandemic H1N1 and avian H9N2 virus. The viruses were serially passaged in canine tracheal explants. Next-generation sequencing was conducted to investigate the reassortment pattern. The resulting reassortants were plaque-purified and inoculated in human alveolar epithelial cells to determine their replication competence and proinflammatory cytokine induction profile.
resultsCo-passaging H3N2-CIV with human/avian influenza A viruses in canine tracheal explants resulted in a high rate of reassortment. Plaque-purified reassortants were all viable and able to propagate in mammalian alveolar epithelial cells. Reassortment most frequently occurred in the MP, NA and NS segments. Selected reassortants had enhanced replication efficiency and able to induce more proinflammatory cytokines than the parental strains, suggesting that these reassortants have a considerable zoonotic risk.
conclusionsOur results demonstrate that ex vivo canine tracheal explants can serve as an effective platform for studying influenza virus reassortment and evolution. The ability of H3N2-CIV reassortants to replicate and induce a proinflammatory cytokine response in human alveolar epithelial cells substantiates the zoonotic potential of canine-origin influenza A viruses and suggests a risk of enhanced transmission acquired through reassortment events. These findings highlight the need for ongoing surveillance and constant vigilance regarding influenza viruses circulating in the canine population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.